Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CSNK1D | P48730 | 1/20 | 0.48 |
| ▸ | CSNK2A2 | P19784 | 1/20 | 0.44 |
| ▸ | CSNK2A1 | P68400 | 1/20 | 0.44 |
| ▸ | AAK1 | Q2M2I8 | 2/20 | 0.40 |
| ▸ | CA12 | O43570 | 5/20 | 0.40 |
| ▸ | CA1 | P00915 | 5/20 | 0.40 |
| ▸ | CA2 | P00918 | 5/20 | 0.40 |
| ▸ | CA9 | Q16790 | 5/20 | 0.40 |
| ▸ | CHEK2 | O96017 | 3/20 | 0.39 |
| ▸ | CHEK1 | O14757 | 2/20 | 0.39 |
| ▸ | STK17B | O94768 | 1/20 | 0.39 |
| ▸ | STK17A | Q9UEE5 | 1/20 | 0.39 |
| ▸ | ACVR1B | P36896 | 1/20 | 0.38 |
| ▸ | TGFBR1 | P36897 | 1/20 | 0.38 |
| ▸ | ACVRL1 | P37023 | 1/20 | 0.38 |
| ▸ | MAPKAPK2 | P49137 | 3/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29799705 | 1.00 | CSNK1D (0.48) | CSNK1DCSNK2A2CSNK2A1AAK1CA12 | |
| SCHEMBL21366385 | 0.81 | MAPKAPK2 (0.41) | CSNK1DAAK1CA12CA1CA2 | |
| SCHEMBL21358401 | 0.80 | CHEK2 (0.44) | CHEK2CHEK1 | |
| SCHEMBL856285 | 0.80 | HSD17B10 (0.53) | — | |
| SCHEMBL16996882 | 0.80 | AAK1 (0.38) | CSNK1DAAK1MAPKAPK2 | |
| SCHEMBL2272717 | 0.79 | CA12 (0.47) | CA12CA1CA2CA9CHEK2 | |
| SCHEMBL30993280 | 0.79 | MAPKAPK2 (0.42) | CSNK1DAAK1MAPKAPK2 | |
| SCHEMBL29520111 | 0.77 | EIF2S1 (0.42) | CSNK1DCA2CHEK2CHEK1 | |
| SCHEMBL1252013 | 0.77 | CHEK2 (0.61) | CA2CHEK2CHEK1 | |
| SCHEMBL856622 | 0.76 | GAA (0.52) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11691967-B2 | Antibiotics effective for gram-negative pathogens | THE BOARD OF TRUSTEES OF THE UNIVERSITY OF ILLINOIS (US) | 2023-07-04 | — | — | US | disclosed |
| US-11691967-B2 | Antibiotics effective for gram-negative pathogens | THE BOARD OF TRUSTEES OF THE UNIVERSITY OF ILLINOIS (US) | 2023-07-04 | — | — | US | disclosed |
| WO-2022187329-A1 | FABI INHIBITORS FOR GRAM-NEGATIVE PATHOGENS | THE BOARD OF TRUSTEES OF THE UNIVERSITY OF ILLINOIS (US) | 2022-09-09 | — | — | WO | disclosed |
| WO-2019177975-A1 | ANTIBIOTICS EFFECTIVE FOR GRAM-NEGATIVE PATHOGENS | THE BOARD OF TRUSTEES OF THE UNIVERSITY OF ILLINOIS (US) | 2019-09-19 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11691967-B2 | Antibiotics effective for gram-negative pathogens | PGLS, MGAM, GMDS | CSNK1D 3650/4885CSNK2A2 3006/4885CSNK2A1 3371/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.